查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球急性激動和攻擊性治療市場 - 2022-2029
市場調查報告書
商品編碼
1140681

全球急性激動和攻擊性治療市場 - 2022-2029

Global Acute Agitation and Aggression Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

老年人口中癡呆症發病率的增加支持了預測期內市場的增長。

癡呆症和抑鬱症是最常見的精神和神經系統疾病之一。癡呆症影響全球約 5% 的老年人口，抑鬱症影響約 7%。目前，臨床試驗正在進行中，以利用這種藥物的特性為其他健康問題提供有效的治療，例如與阿爾茨海默病相關的躁動和 PTSD。成年人通常不遵守並且能夠克服與治療精神障礙相關的社會污名。他們比老年人更有可能被診斷出患有精神疾病並接受治療。

此外，工作壓力的增加正在推動全球市場的增長。急性激動和攻擊性的一個主要驅動因素是工作壓力增加。工作場所的壓力可能來自多種來源，也可能來自單一事件。它也可能影響雇主和僱員。根據美國國家心理健康研究所的數據，到 2020 年，美國將有 5290 萬 18 歲及以上的成年人患上 AMI。這個數字占美國所有成年人的 21.0%。發現某種形式的精神疾病在女性中的患病率（25.8%）高於男性（15.8%）。與 26-49 歲 (25.3%) 和 50 歲及以上 (14.5%) 的人相比，18-25 歲的年輕人的 AMI 患病率也最高 (30.6%)。此外，據報導，美國的壓力增加。例如，根據美國壓力協會 (AIS) 的數據，各種研究表明，工作壓力是美國成年人壓力的主要原因，並且這種趨勢在過去十年中有所增加。

地理滲透

北美在整個預測期內引領全球市場。

北美在急性激動和攻擊性治療市場的全球市場中占主導地位，預計在預測期內將保持其地位。美國在北美急性激越和攻擊性治療市場的市場份額最高。完善的醫療基礎設施，包括完善的心理健康機構和結構，支持急性躁動和攻擊性治療市場。此外，Pfizer Inc., Janssen Biotech, Inc., Eli Lilly Company等主要參與者正在進一步推動該地區的市場增長。

據估計，在預測期內，亞太地區的急性激動和攻擊性治療市場將以可觀的增長率增長。鑑於亞太地區政府為建立非正規醫療基礎設施投入了大量資金，這一增長可歸因於該地區市場參與者的擴張。

競爭格局。

急性激動和攻擊性治療市場是一個競爭激烈的市場。為全球市場增長做出貢獻的領先急性激動和攻擊製造商包括Eli Lilly and Company, Janssen Biotech, Inc. (Johnson & Johnson), Ono Pharmaceutical Co., Ltd., Mylan NV, Impel Pharmaceuticals和Pfizer Inc. 。領先公司正在為急性激動和攻擊性治療市場的全球增長採用新產品發布和擴張戰略。2022 年 7 月，Impel Pharmaceuticals 宣布了第 2a 期患者劑量，該劑量評估 INP105，專門用於治療患有自閉症譜系障礙的青少年的急性躁動。INP105 專為治療自閉症譜系障礙 (ASD) 患者的急性焦慮症而開發，通過 Impel 專有的 POD（精確嗅覺遞送）技術將藥物輸送到上鼻道。這一劑量的結果預計在 2023 年第一季度。同樣在 2022 年 4 月，BioXcel Therapeutics 宣布其 IGALMI（右美托咪定）舌下薄膜已獲得 FDA 批准，用於“急性治療與成人精神分裂症或雙相 I 型障礙相關的激越”。該批准包括兩項關鍵、隨機、雙盲、安慰劑對照、平行組研究，評估右美托咪定用於急性治療與精神分裂症或雙相 I 或 II 障礙相關的激越。它主要是根據 3 期試驗的數據確定的.

COVID-19 的影響將對全球急性激越和攻擊性治療市場產生負面影響。

COVID-19 的爆發無疑影響了全球急性躁動和攻擊性治療市場，因為它迫使患者診斷和門診就診。隨著研究人員轉向開發 COVID-19 疫苗，治療急性躁動和攻擊性藥物的研究和開發受到限制。因此，預計 2020 年急性激越和攻擊性治療市場將顯著下降。

該報告提供了大約 61 個市場數據表、52 個數字和 170 頁有關全球急性激越和攻擊性治療市場的信息。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 市場範圍

第二章主要趨勢和發展

第三章執行摘要

  • 按藥物類別劃分的市場細分
  • 按管理途徑劃分的市場細分
  • 最終用戶的市場細分
  • 區域市場細分

第四章市場動態

  • 市場影響因素
    • 促進者
    • 抑製劑
    • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 價值鏈分析
  • 專利分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 中的價格動態
  • 供需譜
  • 大流行期間與市場相關的政府努力
  • 製造商的戰略舉措

第 7 章 按藥物類別

  • 抗精神病藥
  • 苯二氮卓類
  • 其他

第八章 行政途徑

  • 口服
  • 肌肉注射
  • 其他

第 9 章最終用戶

  • 醫院/門診手術中心
  • 精神病院
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東/非洲

第 11 章按藥物類別的市場規模分析，同比增長分析 (%)，按藥物類別

12. 市場規模分析和同比增長分析（%）：按管理途徑

13. 最終用戶的市場規模分析和同比增長分析 (%)

第十四章 競爭格局

  • 競爭情景
  • 競爭對手戰略分析
  • 市場/份額分析
  • 併購分析

第十五章公司簡介

  • Bristol-Myers Squibb Company
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Janssen Biotech, Inc.（Johnson & Johnson）
  • Ono Pharmaceutical Co., Ltd.
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd

第 16 章 數據管理

簡介目錄
Product Code: DMHCIT2973

Market Overview

Acute Agitation and Aggression Treatment Market are expected to grow at a CAGR of 5% during the forecasting period (2022-2029).

Agitation is characterized as excessive verbal or motor behavior in an individual. It can lead to aggression, which can be either verbal or physical. Several treatment options are available for managing acute agitation and aggression, including environmental de-escalation strategies and biological treatment options and non-pharmacologic behavioral, such as electroconvulsive therapy and pharmacologic agents. The rising prevalence of acute agitation and aggression due to workplace stress and the rising burden of mental illness are some factors that are expected to propel market growth. Moreover, the government awareness programs and increasing incidence of dementia in the geriatric population are further supporting the development of the market across the globe.

Market Dynamics: An increase in the incidence of dementia in the geriatric population continues supporting the market's growth during the forecast period.

Dementia and depression are some of the most prevalent mental and neurological disorders. Dementia affects nearly 5%, whereas depression affects almost 7% of the global elderly population. Clinical trials are currently underway to utilize this agent's properties to provide effective treatment methods for other health issues such as agitation associated with dementia of the Alzheimer's type or PTSD. The adults generally do not follow and overpower a social stigma related to mental disorders treatment. The adults frequently prefer being diagnosed and treated for mental disorders compared to the elderly population.

Moreover, increasing workplace stress is driving the growth of the global market. A major driving factor for acute agitation and aggression is increasing workplace stress. Workplace stress can have a lot of origins or come from a single event. It can affect employees as well as employers alike. According to the National Institute of Mental Health, in 2020, an estimated 52.9 million adults aged 18 or older than this in the United States with AMI. This number represented 21.0% of all U.S. adults. This prevalence of any mental illness was higher in females (25.8%) than males (15.8%). Young adults aged 18-25 years had the highest prevalence of AMI (30.6%) compared to adults aged 26-49 years (25.3%) and aged 50 and older (14.5%). Also, an increased level of stress was reported in the U.S. For instance, as per the American Institute of Stress (AIS), various studies demonstrated that job stress is a major reason for the stress among adults in the U.S., which has intensified in the last decade.

Market Segmentation: The anti-psychotics segment accounted for the highest share in global acute agitation and aggression treatment market.

Dementia and depression are some of the most prevalent mental and neurological disorders. According to World Health Organization, Dementia affects nearly 5%, whereas depression affects almost 7% of the global elderly population. Clinical trials are currently underway to utilize this agent's properties to provide effective treatment methods for other health issues such as agitation associated with dementia of the Alzheimer's type or PTSD. The adults generally do not follow and overpower a social stigma related to mental disorders treatment. The adults frequently prefer being diagnosed and treated for mental disorders compared to the elderly population.

Based on the route of administration, the acute agitation and aggression treatment market have been bifurcated into oral, intramuscular, and others. The oral segment dominated the global acute agitation and aggression treatment market in forecast period. In the acute agitation and aggression treatment market, the major route of administration is an oral treatment. Several drugs are offered by the key market players taken orally to treat acute agitation and aggression. The lack of awareness of the intramuscular treatment solutions for acute agitation and aggression further contributes to the rise in the adoption of oral treatment solutions. The intramuscular administration route is generally preferred to the subcutaneous route, especially when larger drug solutions are needed. Moreover, a longer needle is required for the intramuscular route, limiting its adoption and supporting the growth of the oral route of administration to treat acute agitation and aggression.

Geographical Penetration: North America leads the global market throughout the forecast period.

North America dominated the global acute agitation and aggression treatment market and is expected to retain its position during the forecast period. The US contributed the highest market share in the North American acute agitation and aggression treatment market. The well-developed healthcare infrastructure, including the established mental health institutions and mental health structure, supports its acute agitation and aggression treatment market. Moreover, some of the key players, such as Pfizer Inc., Janssen Biotech, Inc., and Eli Lilly and Company, are further driving the market's growth in the region.

The Asia Pacific is estimated to grow at a considerable growth rate in the acute agitation and aggression treatment market during the forecast period. This growth can be accredited to the expansion of market players in the region, considering the high investment for establishing informal healthcare infrastructure by the governments in the Asia Pacific.

Competitive Landscape:

The acute agitation and aggression treatment market is highly competitive. The key acute agitation and aggression treatment players contributing to the global market's growth include Eli Lilly and Company, Janssen Biotech, Inc. (Johnson & Johnson), Ono Pharmaceutical Co., Ltd., Mylan NV, Impel Pharmaceuticals and Pfizer Inc. The major players are adopting new product launches and expansion strategies for global growth in the acute agitation and aggression treatment market. In July 2022, Impel Pharmaceuticals Announced First Patient Dosed in Phase 2a Evaluating INP105 especially to Treat Acute Agitation in Adolescents with Autism Spectrum Disorder. INP105 is specially developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) by using Impel's proprietary Precision Olfactory Delivery (POD) technology that delivers drugs to the upper nasal space. Results of this dose are expected in Q1 2023. Also, in April 2022, BioXcel Therapeutics Announced that they got FDA Approval for IGALMI (dexmedetomidine) Sublingual Film, which is used in Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults. This approval is generally based on data from two pivotal randomized, double-blinded, placebo-controlled, parallel-group Phase 3 trials evaluating dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.

COVID-19 Impact: Negative impact on the global acute agitation and aggression treatment market.

The outbreak of COVID-19 has certainly impacted the global acute agitation and aggression treatment market, as the lockdown has compelled the diagnosis and the clinic visits of patients. The researchers' shift towards developing the COVID-19 vaccine has deterred the R&D in acute agitation and aggression treatment. Therefore, the acute agitation and aggression treatment market are expected to foresee a considerable decline in 2020.

The global acute agitation and aggression treatment market report would provide an access to approximately 61 market data tables, 52 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by End Users
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Drug Class Segment
    • 7.1.2. Market attractiveness index, By Drug Class Segment
  • 7.2. Anti-Psychotics *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Benzodiazepines
  • 7.4. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Route of Administration Segment
    • 8.1.2. Market attractiveness index, By Route of Administration Segment
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Intramuscular
  • 8.4. Others

9. By End Users

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By End Users Segment
    • 9.1.2. Market attractiveness index, By End Users Segment
  • 9.2. Hospitals & Ambulatory Surgical Centers *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. Psychiatric Care Facilities
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
      • 10.2.2.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      • 10.2.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
      • 10.2.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
      • 10.2.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.2.5. U.S.
      • 10.2.2.6. Canada
      • 10.2.2.7. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.7.1. Brazil
      • 10.3.7.2. Argentina
      • 10.3.7.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.7.1. Germany
      • 10.4.7.2. U.K.
      • 10.4.7.3. France
      • 10.4.7.4. Spain
      • 10.4.7.5. Italy
      • 10.4.7.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics

11. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

12. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

13. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

14. Competitive Landscape

  • 14.1. Competitive scenario
  • 14.2. Competitor strategy analysis
  • 14.3. Market positioning/share analysis
  • 14.4. Mergers and acquisitions analysis

15. Company Profiles

  • 15.1. Bristol-Myers Squibb Company*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Key Highlights
    • 15.1.4. Financial Overview
  • 15.2. Eli Lilly and Company
  • 15.3. GlaxoSmithKline plc
  • 15.4. H. Lundbeck A/S
  • 15.5. Janssen Biotech, Inc. (Johnson & Johnson)
  • 15.6. Ono Pharmaceutical Co., Ltd.
  • 15.7. Otsuka Holdings Co., Ltd.
  • 15.8. Pfizer Inc.
  • 15.9. Mylan NV
  • 15.10. Teva Pharmaceutical Industries Ltd
  • List not Exhaustive*

16. DataM

  • 16.1. Appendix
  • 16.2. About us and services
  • 16.3. Contact us